Hypertrophic cardiomyopathy (HCM) is one of the most common genetic cardiovascular diseases, both in the US and globally. However, due to the wide variety of clinical symptoms that can be interpreted as other diseases, HCM patients often face misdiagnosis or treatment delays.

The ACC's Accelerating Innovation for Medical Excellence in Hypertrophic Cardiomyopathy (AIME HCM) initiative is designed to increase awareness and understanding of HCM, activate clinicians, and optimize disease management to improve outcomes.

Use the navigation buttons below to explore educational tools and resources, including expert videos, interactive learning modules and podcasts; stay up to date on research efforts to understand clinician and patient perspectives related to the management and treatment of HCM; and learn more about focused clinician roundtables and patient forums intended to inform efforts to accelerate innovation in HCM management.

The AIME HCM Initiative is supported by Bristol Myers Squibb.